Dana-Farber Cancer Institute

Articles

Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer

January 16th 2024

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma.

FDA Approves Kidney Cancer Therapy After Dana-Farber-Led Research Shows Improved Outcomes for Patients with Advanced Disease

December 31st 2023

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

Study Finds Associations Between T Cell Diversity in Peripheral Blood and Patient Age, Stage of Breast Cancer Development

December 28th 2023

Researchers at Dana-Farber Cancer Institute found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Study Finds Associations Between T Cell Diversity in Peripheral Blood and Patient Age and Stage of Breast Cancer Development

December 24th 2023

Researchers at Dana-Farber Cancer Institute have found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Dana-Farber Launches New Centers to Detect and Intercept Cancer

December 10th 2023

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

December 6th 2023

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

Dana-Farber Research Fellow Tyler Miller, MD, PhD, Receives £600,000 Grant From the Brain Tumour Charity

November 27th 2023

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

Dual-Action Drug Produces Positive Results in Patients With Advanced Neuroendocrine Tumors, Trial Finds

November 16th 2023

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

Oncology Researchers Raise Ethics Concerns Posed By Patient-Facing Artificial Intelligence

November 13th 2023

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.

Kidney Cancer Study Shows Improved Outcomes for Patients With Advanced Disease When Treated With Belzutifan Over Everolimus

November 7th 2023

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma, the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

First International Collaborative Member of Dana-Farber Cancer Institute Opens in Brazil With Oncoclínicas Cancer Center

November 2nd 2023

Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world's leading cancer treatment and oncology research institutions, and Oncoclínicas & Co, the largest group dedicated to cancer in Latin America, announce the expansion of their collaboration with the opening of the first Oncoclínicas Cancer Center as an International Collaborative Member of Dana-Farber Cancer Institute.

Bradley Bernstein of Dana-Farber Elected to National Academy of Medicine

October 24th 2023

Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine.

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023

October 18th 2023

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.

Study Offers Way to Increase Immune Checkpoint Inhibitor Effectiveness in Patients With MTAP-Deleted Cancers

October 12th 2023

Loss of the “housekeeping” gene methylthioadenosine phosphorylase, or MTAP, is a common event in cancer.

Study Uncovers Function of Mysterious Disordered Regions of Proteins Implicated in Cancer

October 4th 2023

New research from Dana-Farber Cancer Institute researcher Cigall Kadoch, PhD, along with colleagues at Princeton University and Washington University in St. Louis, reveals a key role for intrinsically disordered proteins known as IDRs that are implicated in a wide range of human diseases, from cancer to neurodegeneration

Deep Learning Reveals Valuable Clues About Kidney Cancer in Pathology Slides

September 25th 2023

A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma, a form of kidney cancer, using image processing with deep learning.

Potent Oral Agent Acting as Immunotherapy and Targeted Treatment Produces High Response Rate in Certain Patients

September 22nd 2023

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center Forge New Collaboration to Advance Future of Adult Cancer Care; Announce Plans to Build Region’s Only Free-Standing Cancer Hospital

September 15th 2023

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.

Origins of Glioma Brain Cancer Found to Be in the Epigenome

July 31st 2023

Researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas– incurable brain tumors– can arise due to changes in the epigenome.

New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing

June 19th 2023

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.